ReNeuron Group (RENE) Short Positions
Add to Alert list

Active Short Positions

Holder Position Change Date
No active short positions

Historical Short Positions

Holder Position Change (%) Date
No historical short positions

ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

It listed on AIM in 2006 under the ticker RENE.

Note: This description is in part generated by AI and not an endorsement by or the opinion of Investegate
UK 100

Latest directors dealings